The maker of the long-acting painkiller Opana ER has agreed to stop marketing the drug as crush-resistant, under a settlement with New York State. The company also agreed to accurately describe the risk of addiction to the drug, Reuters reports.
Under the agreement with New York State, Endo Health Solutions and Endo Pharmaceuticals will also pay a $200,000 penalty, according to New York State Attorney General Eric T. Schneiderman. He said the company’s own studies found Opana ER could be crushed and ground. “This may have bolstered Opana ER sales, but provided a false sense of security to health care providers and their patients,” according to a statement by Schneiderman’s office.
The Attorney General also found that Endo improperly instructed its sales representatives to “diminish and distort risks associated with Opana ER, including serious dangers involving addiction,” Schneiderman’s office stated.